News
= LISA News
23.03.2018
Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15
16.03.2018
Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies
16.03.2018
Valneva Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya
16.03.2018
Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017
07.03.2018
CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS
07.03.2018
AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs® PD01A and PD03A, Confirming Safety and Tolerability for Both Compounds as well as Immunogenicity for PD01A in Early MSA patients